Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
Related Stories
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 2 months
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 3 months
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 6 days
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 5 wks
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 6 wks
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 3 months
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try FDA, Pharmaceuticals, Avian Influenza, Olfaction and look for the RSS link.
StackHealth Time Machine